Shire Agrees to FDA Request to Conduct Clinical Trials Investigating the Use of Vyvanse in Preschool-Age Children

Thu, 06/12/2014 - 9:13am

Shire announced that it has agreed to a written request by the Food and Drug Administration (FDA) to conduct pediatric clinical studies to investigate the potential use of Vyvanse (lisdexamfetamine dimesylate) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in preschool-age children, ages 4 to 5.

"Shire is committed to continuing to add to the scientific body of knowledge about ADHD treatment options for patients," said Philip Vickers, Ph.D., Head of Research and Development at Shire. "Additional efficacy and safety data will help clinicians and parents make informed treatment decisions for preschool-age children with ADHD." Currently there are few adequate and well-controlled studies of pharmacotherapy in preschool-age children with ADHD. Shire is in the process of developing design protocols for three clinical trials with Vyvanse that will make up the clinical trial program in preschool children: a pharmacokinetic study to help determine appropriate dosing and evaluate safety and tolerability; an efficacy and safety study; and an open-label study to evaluate long-term safety. A Data Monitoring Committee will also be established to monitor patient safety throughout the duration of the clinical program. Shire anticipates beginning the first trial in the preschool pediatric clinical trial program in the first half of 2015.

Upon FDA confirmation of a timely submission and review of data that adheres to the requirements of the Written Request, Shire will be entitled to the benefits of the Best Pharmaceuticals for Children Act, including a six-month extension to the exclusivity afforded by Shire's patents for Vyvanse, which expire in 2023. 


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.